Abstract:<p>Epigenetic dysregulation, which leads to the alteration of gene expression in the brain, is suggested as one of the key pathophysiological bases of ageing and neurodegeneration. Here we found that, in the late-stage familial Alzheimer's disease (FAD) mouse model, repressive histone H3 dimethylation at lysine 9 (H3K9me2) and euchromatic histone methyltransferases EHMT1 and EHMT2 were significantly elevated in the prefrontal cortex, a key cognitive region affected in Alzheimer's disease. Elevated levels of H3K9me2 were also detected in the prefrontal cortex region of post-mortem tissues from human patients with Alzheimer's disease. Concomitantly, H3K9me2 at glutamate receptors was increased in prefrontal cortex of aged FAD mice, which was linked to the diminished transcription, expression and function of AMPA and NMDA receptors. Treatment of FAD mice with specific EHMT1/2 inhibitors reversed histone hyper-methylation and led to the recovery of glutamate receptor expression and excitatory synaptic function in prefrontal cortex and hippocampus. Chromatin immunoprecipitation-sequencing (ChIP-seq) data indicated that FAD mice exhibited genome-wide increase of H3K9me2 enrichment at genes involved in neuronal signalling (including glutamate receptors), which was reversed by EHMT1/2 inhibition. Moreover, the impaired recognition memory, working memory, and spatial memory in aged FAD mice were rescued by the treatment with EHMT1/2 inhibitors. These results suggest that disrupted epigenetic regulation of glutamate receptor transcription underlies the synaptic and cognitive deficits in Alzheimer's disease, and targeting histone methylation enzymes may represent a novel therapeutic strategy for this prevalent neurodegenerative disorder.</p>

Biological and Therapeutic Role of LSD1 in Alzheimer’s Diseases

The inhibition of LSD1 via sequestration contributes to tau-mediated neurodegeneration

Molecular mechanisms and therapeutic potential of lithium in Alzheimer's disease: repurposing an old class of drugs

Epigenetic Inhibitors as Alzheimer's Disease Therapeutic Agents

Targeting epigenetic mechanisms in amyloid-β-mediated Alzheimer's pathophysiology: unveiling therapeutic potential

The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases

The role of N-methyl-D-aspartate glutamate receptors in Alzheimer's disease: from pathophysiology to therapeutic approaches

Lysophospholipids and Their G-Coupled Protein Signaling in Alzheimer’s Disease: from Physiological Performance to Pathological Impairment

Autophagy in Alzheimer's Disease and Promising Modulatory Effects of Herbal Medicine

Inhibition of EHMT1/2 rescues synaptic and cognitive functions for Alzheimer’s disease

L-arginine and Alzheimer's disease.

Impairment of the autophagy–lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential

Medicinal Chemistry Insights in the Discovery of Novel LSD1 Inhibitors

Exploring the Therapeutic Potential of Natural Compounds for Alzheimer's Disease: Mechanisms of Action and Pharmacological Properties.

Therapeutic potential of the medicinal mushroom Ganoderma lucidum against Alzheimer's disease

Nanomaterials-mediated lysosomal regulation: a robust protein-clearance approach for the treatment of Alzheimer’s disease

Astrocytic GluN2A and GluN2B Oppose the Synaptotoxic Effects of Amyloid-β1-40 in Hippocampal Cells.

LSD1n is an H4K20 Demethylase Regulating Memory Formation Via Transcriptional Elongation Control

Autophagy Modulation for Alzheimer's Disease Therapy.

Molecular Mechanism of Autophagy: Its Role in the Therapy of Alzheimer’s Disease

Enhancement of Lysosome Biogenesis As a Potential Therapeutic Approach for Neurodegenerative Diseases.